Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study
Authors:
- Innocenza PalaiaIPInnocenza Palaia
- Giuseppe CarusoGCGiuseppe Caruso
- Violante Di DonatoVDViolante Di Donato
- Annarita VestriAVAnnarita Vestri
- Anna NapoliANAnna Napoli
- Giorgia PerniolaGPGiorgia Perniola
- Matteo CasinelliMCMatteo Casinelli
- Danilo Alunni FegatelliDFDanilo Alunni Fegatelli
- Roberta CampagnaRCRoberta Campagna
- Federica TomaoFTFederica Tomao
- Debora D’anielloDDDebora D’aniello
- Guido AntonelliGAGuido Antonelli
Open Access
Abstract
Objective: To evaluate the safety and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in gynecologic oncology patients under chemotherapy. Methods: A prospective cohort study including gynecologic oncology women who were under chemotherapy or had completed it within 6 months at the time of the study. All patients received a two-dose schedule of the Pfizer-BioNTech COVID-19 vaccine. Results were compared with a control group of healthy women vaccinated in the same period. Results: Overall, 44 oncologic patients with a mean age of 61.3 ± 10.7 years were enrolled: 28 (63.6%) had ovarian cancer, 9 (20.4%) endometrial, and 7 (16%) cervical. The IgG antibody titer after 1 month from vaccination was low in 9 (20.5%) patients, moderate in 21 (47.7%), and high in 14 (31.8%). The 3-month titer was null in 2 (4.5%) patients, low in 26 (59.1%), moderate in 13 (29.5%), and high in 3 (6.8%). Patients ≥ 50 years reported lower 1-month (p = 0.018) and 3-month (p = 0.004) titers compared with 2 had a higher 1-month titer compared with BMI ≥ 30 kg/m2 (p = 0.016). Compared with healthy women (n = 44), oncologic patients showed a lower 3-month titer (p < 0.001). None of the patients experienced serious adverse effects. Conclusions: The COVID-19 vaccine was safe and immunogenic in gynecologic oncology patients under chemotherapy. Serological monitoring and further vaccine shots should be considered to boost protection.Keywords
This publication has 25 references indexed in Scilit:
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsScience, 2020
- Cancer prevales on COVID‐19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemicJournal of Medical Virology, 2020
- Interpreting Diagnostic Tests for SARS-CoV-2JAMA, 2020
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyThe Lancet, 2020
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyThe Lancet, 2020
- Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19Annals of Oncology, 2020
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 OutbreakCancer Discovery, 2020
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaNew England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016